Revisiting the role of TRAIL/TRAIL-R in cancer biology and therapy

TRAIL receptors are differentially regulated and clinically significant in gallbladder cancer

(2020) Deepika Singh et al.   PATHOLOGY

TRAIL in oncology: From recombinant TRAIL to nano- and self-targeted TRAIL-based therapies

(2020) Hassan Dianat-Moghadam et al.   PHARMACOLOGICAL RESEARCH

PD-L1 Under Regulation of miR-429 Influences the Sensitivity of Gastric Cancer Cells to TRAIL by Binding of EGFR

(2020) Jinqi Lv et al.   Frontiers in Oncology

Luteolin enhances TRAIL sensitivity in non-small cell lung cancer cells through increasing DR5 expression and Drp1-mediated mitochondrial fission

(2020) Bin Wu et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Customizing a Tridomain TRAIL Variant to Achieve Active Tumor Homing and Endogenous Albumin-Controlled Release of the Molecular Machine In Vivo

(2020) Ze Tao et al.   BIOMACROMOLECULES

TRAIL therapy and prospective developments for cancer treatment

(2020) Bindu Thapa et al.   JOURNAL OF CONTROLLED RELEASE

Generation and characterization of novel anti-DR4 and anti-DR5 antibodies developed by genetic immunization

(2019) Agathe Dubuisson et al.   Cell Death & Disease

Downregulation of miR-125b promotes resistance of glioma cells to TRAIL through overexpression of Tafazzin which is a mitochondrial protein

(2019) Wenjia Ma et al.   Aging-US

Targeting TRAIL

(2019) George Nicolae Daniel Ion et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy

(2019) Mohammed I. Y. Elmallah et al.   Cancers

TRAIL-based gene delivery and therapeutic strategies

(2019) Hui-hai Zhong et al.   ACTA PHARMACOLOGICA SINICA

Metal‐based phosphorus dendrimers as novel nanotherapeutic strategies to tackle cancers: A concise overview

(2019) Liang Chen et al.   Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology

The TRAIL to cancer therapy: Hindrances and potential solutions

(2019) Sonia How Ming Wong et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

miR-221 Augments TRAIL-Mediated Apoptosis in Prostate Cancer Cells by Inducing Endogenous TRAIL Expression and Targeting the Functional Repressors SOCS3 and PIK3R1

(2019) Markus Krebs et al.   Biomed Research International

Developing TRAIL/TRAIL death receptor-based cancer therapies

(2018) Xun Yuan et al.   CANCER AND METASTASIS REVIEWS

Comprehensive expression analysis of TNF-related apoptosis-inducing ligand and its receptors in colorectal cancer: Correlation with MAPK alterations and clinicopathological associations

(2018) Spyridon Tsikalakis et al.   PATHOLOGY RESEARCH AND PRACTICE

The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells

(2018) Karen Legler et al.   Cell Death & Disease

Relationship between the agonist activity of synthetic ligands of TRAIL-R2 and their cell surface binding modes

(2018) Neila Chekkat et al.   Oncotarget

Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC

(2018) Jan-Paul Gundlach et al.   BMC CANCER

Nanocarriers for TRAIL delivery: driving TRAIL back on track for cancer therapy

(2017) Xu Wu et al.   Nanoscale

TRAIL–NP hybrids for cancer therapy: a review

(2017) H. Belkahla et al.   Nanoscale

Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer

(2017) Linda J.W. Bosch et al.   Oncotarget

ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells

(2017) Xun Yuan et al.   Oncotarget

Multifunctional Nucleus-targeting Nanoparticles with Ultra-high Gene Transfection Efficiency for In Vivo Gene Therapy

(2017) Ling Li et al.   Theranostics

Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo

(2017) Haipeng Liu et al.   Scientific Reports

Multifunctional “core-shell” nanoparticles-based gene delivery for treatment of aggressive melanoma

(2016) Ling Li et al.   BIOMATERIALS

Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer

(2016) Juan Yang et al.   BIOMEDICINE & PHARMACOTHERAPY

Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme

(2016) Filiz Senbabaoglu et al.   CANCER BIOLOGY & THERAPY

Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancer

(2016) Ufuk Mert et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Chikusetsusaponin IVa Butyl Ester (CS-IVa-Be), a Novel IL6R Antagonist, Inhibits IL6/STAT3 Signaling Pathway and Induces Cancer Cell Apoptosis

(2016) Jie Yang et al.   MOLECULAR CANCER THERAPEUTICS

Proteasome inhibitor MG132 potentiates TRAIL-induced apoptosis in gallbladder carcinoma GBC-SD cells via DR5-dependent pathway

(2016) Weiping Zhu et al.   ONCOLOGY REPORTS

ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies

(2016) Jo Ishizawa et al.   Science Signaling

Overcoming Gene-Delivery Hurdles: Physiological Considerations for Nonviral Vectors

(2016) Andrew B. Hill et al.   TRENDS IN BIOTECHNOLOGY

Ginsenoside compound K sensitizes human colon cancer cells to TRAIL-induced apoptosis via autophagy-dependent and -independent DR5 upregulation

(2016) Lei Chen et al.   Cell Death & Disease

TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress

(2016) Florent Dufour et al.   Oncotarget

Discovery and clinical introduction of first-in-class imipridone ONC201

(2016) Joshua E. Allen et al.   Oncotarget

ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies

(2016) Jo Ishizawa et al.   Science Signaling

Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancer

(2016) Marina Devetzi et al.   Scientific Reports

Poly-ADP-ribosylation of HMGB1 regulates TNFSF10/TRAIL resistance through autophagy

(2015) Minghua Yang et al.   Autophagy

ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer

(2015) Jie Yang et al.   CANCER BIOLOGY & THERAPY

Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor

(2015) Kyriakos P. Papadopoulos et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner

(2015) V. V. Prabhu et al.   CANCER RESEARCH

Molecular mechanism of ER stress-induced gene expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in macrophages

(2015) Yan Huang et al.   FEBS Journal

Cell death induced by endoplasmic reticulum stress

(2015) Raffaella Iurlaro et al.   FEBS Journal

Epigenetic inactivation of TRAIL decoy receptors at 8p12-21.3 commonly deleted region confers sensitivity to Apo2L/trail-Cisplatin combination therapy in cervical cancer

(2015) Gopeshwar Narayan et al.   GENES CHROMOSOMES & CANCER

Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity

(2015) L O'Leary et al.   ONCOGENE

The alkyllysophospholipid edelfosine enhances TRAIL-mediated apoptosis in gastric cancer cells through death receptor 5 and the mitochondrial pathway

(2015) Sung-Chul Lim et al.   TUMOR BIOLOGY

Inhibition of Notch1 signaling overcomes resistance to the death ligand Trail by specificity protein 1-dependent upregulation of death receptor 5

(2015) A Fassl et al.   Cell Death & Disease

Nanoparticle-Mediated Target Delivery of TRAIL as Gene Therapy for Glioblastoma

(2015) Kui Wang et al.   Advanced Healthcare Materials

Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells

(2015) Rachana Trivedi et al.   Frontiers in Oncology

Sandwich-Type Au-PEI/DNA/PEI-Dexa Nanocomplex for Nucleus-Targeted Gene Delivery in Vitro and in Vivo

(2014) Zhenzhen Chen et al.   ACS Applied Materials & Interfaces

Getting TRAIL back on track for cancer therapy

(2014) J Lemke et al.   CELL DEATH AND DIFFERENTIATION

Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer

(2014) Joachim von Pawel et al.   Clinical Lung Cancer

Membrane expression of trail receptors DcR1 and DcR2 in the normal endometrium, endometrial atypical hyperplasia and endometrioid endometrial cancer

(2014) L. Gottwald et al.   JOURNAL OF OBSTETRICS AND GYNAECOLOGY

Viral and Cellular FLICE-Inhibitory Proteins: a Comparison of Their Roles in Regulating Intrinsic Immune Responses

(2014) J. L. Shisler   JOURNAL OF VIROLOGY

Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction

(2014) Heather A Huet et al.   mAbs

Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth

(2014) Changyou Li et al.   Molecular Oncology

Non-viral vectors for gene-based therapy

(2014) Hao Yin et al.   NATURE REVIEWS GENETICS

Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway

(2014) R Trivedi et al.   Cell Death & Disease

Expression of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Death Receptors DR4 and DR5 in Human Nonmelanoma Skin Cancer

(2013) Ola M. Omran et al.   AMERICAN JOURNAL OF DERMATOPATHOLOGY

Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL

(2013) A Meijer et al.   BRITISH JOURNAL OF CANCER

Nuclear Death Receptor TRAIL-R2 Inhibits Maturation of Let-7 and Promotes Proliferation of Pancreatic and Other Tumor Cells

(2013) Verena Haselmann et al.   GASTROENTEROLOGY

Liposomes Decorated with Apo2L/TRAIL Overcome Chemoresistance of Human Hematologic Tumor Cells

(2013) Diego De Miguel et al.   MOLECULAR PHARMACEUTICS

Loss of TRAIL-Receptors Is a Recurrent Feature in Pancreatic Cancer and Determines the Prognosis of Patients with No Nodal Metastasis after Surgery

(2013) Eike Gallmeier et al.   PLoS One

Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects

(2013) J. E. Allen et al.   Science Translational Medicine

TRAIL promotes membrane blebbing, detachment and migration of cells displaying a dysfunctional intrinsic pathway of apoptosis

(2012) Syam Prakash Somasekharan et al.   APOPTOSIS

Regulation of the human TRAIL gene

(2012) Joshua E. Allen et al.   CANCER BIOLOGY & THERAPY

Proapoptotic Activation of Death Receptor 5 on Tumor Endothelial Cells Disrupts the Vasculature and Reduces Tumor Growth

(2012) Nicholas S. Wilson et al.   CANCER CELL

Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors

(2012) Hairong Cheng et al.   CELL CYCLE

Control of FLIPL expression and TRAIL resistance by the extracellular signal-regulated kinase1/2 pathway in breast epithelial cells

(2012) R Yerbes et al.   CELL DEATH AND DIFFERENTIATION

Capsazepine, a TRPV1 antagonist, sensitizes colorectal cancer cells to apoptosis by TRAIL through ROS–JNK–CHOP-mediated upregulation of death receptors

(2012) Bokyung Sung et al.   FREE RADICAL BIOLOGY AND MEDICINE

Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist

(2012) V. Subbiah et al.   MOLECULAR CANCER THERAPEUTICS

TRAF2 Sets a Threshold for Extrinsic Apoptosis by Tagging Caspase-8 with a Ubiquitin Shutoff Timer

(2012) Francois Gonzalvez et al.   MOLECULAR CELL

MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation

(2012) G. Romano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The adaptor protein FADD and the initiator caspase-8 mediate activation of NF-κB by TRAIL

(2012) M Grunert et al.   Cell Death & Disease

Zyflamend Sensitizes Tumor Cells to TRAIL-Induced Apoptosis Through Up-Regulation of Death Receptors and Down-Regulation of Survival Proteins: Role of ROS-Dependent CCAAT/Enhancer-Binding Protein-Homologous Protein Pathway

(2011) Ji Hye Kim et al.   ANTIOXIDANTS & REDOX SIGNALING

Effect of anti-DR5 and chemotherapy on basal-like breast cancer

(2011) Patsy G. Oliver et al.   BREAST CANCER RESEARCH AND TREATMENT

Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL

(2011) Pamela M. Holland   CANCER LETTERS

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Wogonin and Related Natural Flavones Overcome Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Protein Resistance of Tumors by Down-regulation of c-FLIP Protein and Up-regulation of TRAIL Receptor 2 Expression

(2011) Jie Ding et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Importin β1 Protein-mediated Nuclear Localization of Death Receptor 5 (DR5) Limits DR5/Tumor Necrosis Factor (TNF)-related Apoptosis-inducing Ligand (TRAIL)-induced Cell Death of Human Tumor Cells

(2011) Yuko Kojima et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2

(2011) M.E.D. Chamuleau et al.   LEUKEMIA RESEARCH

The use of myristic acid as a ligand of polyethylenimine/DNA nanoparticles for targeted gene therapy of glioblastoma

(2011) Jin Li et al.   NANOTECHNOLOGY

Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types

(2010) Paula J. Kaplan-Lefko et al.   CANCER BIOLOGY & THERAPY

BID is cleaved by caspase-8 within a native complex on the mitochondrial membrane

(2010) Z T Schug et al.   CELL DEATH AND DIFFERENTIATION

Expression, Cellular Distribution, and Prognostic Relevance of TRAIL Receptors in Hepatocellular Carcinoma

(2010) L. Kriegl et al.   CLINICAL CANCER RESEARCH

Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

(2010) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells

(2009) Takeshi Hori et al.   CANCER LETTERS

Cullin3-Based Polyubiquitination and p62-Dependent Aggregation of Caspase-8 Mediate Extrinsic Apoptosis Signaling

(2009) Zhaoyu Jin et al.   CELL

Prognostic Value of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer

(2009) S. Macher-Goeppinger et al.   CLINICAL CANCER RESEARCH

Death Receptor 5 Internalization Is Required for Lysosomal Permeabilization by TRAIL in Malignant Liver Cell Lines

(2009) Yuko Akazawa et al.   GASTROENTEROLOGY

Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer

(2009) Tom M. Ganten et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib

(2009) T. A. Luster et al.   MOLECULAR CANCER THERAPEUTICS

XIAP discriminates between type I and type II FAS-induced apoptosis

(2009) Philipp J. Jost et al.   NATURE

Combined treatment with lexatumumab and irradiation leads to strongly increased long term tumour control under normoxic and hypoxic conditions

(2009) Patrizia Marini et al.   Radiation Oncology

A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes

(2008) A. Yada et al.   ANNALS OF ONCOLOGY

Sp1-Mediated TRAIL Induction in Chemosensitization

(2008) J. Xu et al.   CANCER RESEARCH

Six1 Overexpression in Mammary Cells Induces Genomic Instability and Is Sufficient for Malignant Transformation

(2008) R. D. Coletta et al.   CANCER RESEARCH

Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5

(2008) C Adams et al.   CELL DEATH AND DIFFERENTIATION

Nonviral Vectors for Gene Delivery

(2008) Meredith A. Mintzer et al.   CHEMICAL REVIEWS

Cooperation of the Agonistic DR5 Antibody Apomab with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival

(2008) H. Jin et al.   CLINICAL CANCER RESEARCH

Treatment of Human Colon Cancer Xenografts with TRA-8 Anti-death Receptor 5 Antibody Alone or in Combination with CPT-11

(2008) P. G. Oliver et al.   CLINICAL CANCER RESEARCH

Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas

(2008) Virginie Granci et al.   EUROPEAN JOURNAL OF CANCER

Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL)

(2008) Avi Ashkenazi et al.   JOURNAL OF CLINICAL ONCOLOGY

Directing cancer cells to self-destruct with pro-apoptotic receptor agonists

(2008) Avi Ashkenazi   NATURE REVIEWS DRUG DISCOVERY